Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

IV Infusion to Oral Dosing: Conversion Methods

IV Infusion to Oral Dosing: Conversion Methods

The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.

BMJ open·2026

Same author

Authors' Reply to the Letter by Dr. Toshikuni on Endotype Clustering, Hepatic Steatosis, and Vulnerable Coronary Plaque.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Same author

Hepatic Steatosis Is Associated With Increased Cardiovascular Risk Through Adverse Coronary Plaque Composition.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Same author

Opportunistic CT-Derived Periaortic Fat Attenuation as a Novel Marker of Mortality in Patients Undergoing TAVR.

JACC. Cardiovascular imaging·2026

Same author

AI-Driven Quantitative Coronary CT Angiography in Suspected Coronary Artery Disease: Multicenter CONFIRM2 Registry.

JACC. Advances·2026

Same author

Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.

Circulation·2026

Search research articles

Related Experiment Video

Updated: May 12, 2026

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Published on: May 22, 2017

High-density lipoprotein infusion therapy: A review.

H Bryan Brewer¹, Ernst J Schaefer², Borek Foldyna³

¹HDL Therapeutics, Vero Beach, FL, USA (Dr Brewer).

Journal of Clinical Lipidology

|May 23, 2024

Summary

High-density lipoprotein (HDL) infusions show potential for atherosclerosis regression, but results vary. Differences in HDL preparations, patient populations, and assessment methods may explain inconsistent outcomes in clinical trials.

Keywords:

ApoA-I Cholesterol efflux Coronary plaque regression HDL infusion therapy High-density lipoproteins Homozygous familial hypercholesterolemia

More Related Videos

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Published on: May 9, 2019

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Related Experiment Videos

Last Updated: May 12, 2026

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Published on: May 22, 2017

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Published on: May 9, 2019

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Area of Science:

Cardiovascular Medicine
Biochemistry
Medical Imaging

Background:

Increased cholesterol-rich, non-calcified atheromas predict myocardial infarction better than traditional markers.
Low high-density lipoprotein (HDL) cholesterol is an independent risk factor for coronary artery disease (CAD).
Small, lipid-poor preβ-1 HDL particles are effective in cellular cholesterol efflux.

Purpose of the Study:

To review animal and human studies on HDL infusion therapy for atherosclerosis regression.
To explore reasons for variable outcomes in HDL infusion studies.

Main Methods:

Review of animal studies demonstrating HDL's effect on aortic atherosclerosis.
Analysis of human clinical trials using HDL mimetics and native HDL infusions.
Examination of studies employing intravascular ultrasound and computed coronary angiography for atherosclerosis assessment.

Main Results:

HDL infusions reduced aortic atherosclerosis in animal models.
Some human studies with HDL mimetics or complexes yielded negative results for coronary atherosclerosis progression.
A study using autologous delipidated HDL infusions showed significant regression of coronary atheroma in familial hypercholesterolemic patients.

Conclusions:

HDL infusion therapy shows promise for atherosclerosis regression, particularly with autologous delipidated HDL.
Variability in results may stem from differences in HDL preparations, patient selection, and imaging assessment techniques.
Further research is needed to optimize HDL-based therapies for cardiovascular disease.